Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial

• Main Authors: Kathy Baisley, MSc (Author), Troy J Kemp, PhD (Author), Aimée R Kreimer, PhD (Author), Partha Basu, PhD (Author), John Changalucha, MSc (Author), Allan Hildesheim, PhD (Author), Carolina Porras, MSc (Author), Hilary Whitworth, PhD (Author), Rolando Herrero, PhD (Author), Charles J Lacey, MD (Author), John T Schiller, PhD (Author), Eric Lucas, MSc (Author), Paul Mutani, MD (Author), Joakim Dillner, PhD (Author), Jackton Indangasi, MSc (Author), Richard Muwonge, PhD (Author), Richard J Hayes, DSc (Author), Ligia A Pinto, PhD (Author), Deborah Watson-Jones, PhD (Author)
• Format: Book
• Published: Elsevier, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Human papillomavirus (HPV) vaccines are given as a two-dose schedule in children aged 9-14 years, or as three doses in older individuals. We compared antibody responses after one dose of HPV vaccine in the Dose Reduction Immunobridging and Safety Study (DoRIS), a randomised tria...